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Background: Oral corticosteroids (OCS) are commonly administered in patients with severe persistent allergic
asthma. Despite their efficacy, they are associated with a wide variety of adverse events. The eXpeRience registry
was set up to investigate real-world outcomes among patients receiving omalizumab for the treatment of
uncontrolled allergic asthma. Here, we present the effect of omalizumab treatment on OCS use.
Methods: eXpeRience was a 2-year, multinational, non-interventional, observational registry of patients receiving
omalizumab for uncontrolled allergic asthma. OCS use (proportion of patients on maintenance OCS, mean total daily
OCS dose and change in status of OCS therapy) was assessed at baseline, 16 weeks, and 8, 12, 18, and 24 months after
the initiation of omalizumab. Response to omalizumab was assessed using the physician’s Global Evaluation of
Treatment Effectiveness (GETE) at approximately Week 16. Safety data were also recorded.
Results: A total of 943 patients (mean age, 45 years; female, 64.9%) were enrolled in the registry, 263 of whom were
receiving maintenance OCS at baseline. The proportion of patients taking maintenance OCS was markedly lower at
Months 12 (16.1%) and 24 (14.2%) than at baseline (28.6%; intent-to-treat population). GETE status was determined in
915 patients receiving omalizumab: 64.2% were responders (excellent or good response), 30.7% were non-responders
(moderate, poor or worsening response); 5.1% had no assessment. The frequency of serious adverse events was
comparable to that seen in controlled trials of omalizumab.
Conclusions: Omalizumab use is associated with an OCS-sparing effect in patients with uncontrolled persistent
allergic asthma in the real-world setting.
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Patients with allergic asthma are often inadequately con-
trolled despite treatment with high-dose inhaled cortico-
steroids (ICS) and long-acting β2-agonists (LABA) [1,2].
Oral corticosteroids (OCS) are commonly administered
to suppress airway inflammation and improve asthma
control in these patients; however, their long-term use is
associated with significant adverse effects, such as dia-
betes, osteoporosis and cataract formation, placing a
major burden on patients and healthcare resources [3-6].* Correspondence: g.braunstahl@sfg.nl
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reproduction in any medium, provided the orInterventions that allow OCS treatment to be reduced
or withdrawn completely are likely to benefit patients re-
ceiving these agents for the treatment of asthma.
Omalizumab, a humanized anti-immunoglobulin E (IgE)
monoclonal antibody, is approved for the treatment of
patients with uncontrolled moderate-to-severe (US) or se-
vere (EU) persistent allergic (IgE-mediated) asthma [7,8].
Omalizumab has been shown to reduce asthma exacerba-
tions and hospital visits, as well as corticosteroid use, in
patients with allergic asthma [9-11]. Omalizumab has also
been shown to have a direct OCS-sparing effect in a 32-
week randomized, open-label study in adolescents and
adults (12–75 years) with severe asthma [12], as well as intral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dian age 12 years) [13].
eXpeRience was an international registry initiated to
evaluate outcomes in patients receiving omalizumab for
uncontrolled persistent allergic asthma in ‘real-world’
clinical practice. The primary results, published previ-
ously [14,15], showed that omalizumab was associated
with improvements in clinical outcomes such as asthma
exacerbations and objective measures of asthma control.
Here, we evaluate the real-world effect of omalizumab
treatment on the use of OCS over a 2-year period.
Methods
eXpeRience was a multinational, non-interventional, ob-
servational registry established to collect data on the
real-world effectiveness and safety of omalizumab ther-
apy during routine clinical practice in patients with un-
controlled persistent allergic (IgE-mediated) asthma. The
registry design has been published previously [15].
Briefly, the registry included male and female patients
with uncontrolled persistent allergic asthma who had
commenced omalizumab treatment within the previous
15 weeks. Patients from 14 countries in Europe, America
and Asia were enrolled, and were followed for up to
2 years after initiation of omalizumab. After entry into
the registry, data were collected prospectively at approxi-
mately 16 weeks and at 8, 12, 18 and 24 months after
initiation of omalizumab treatment, with a minimum re-
quirement of two data collections per year.
Treatment and follow-up of patients was at the discre-
tion of the treating physician, according to local medical
practice and label/reimbursement guidelines. The regis-
try design and amendments were reviewed by independ-
ent ethics committees or institutional review boards at
each participating centre, as required.
Registry assessments
Data on OCS use were collected at each pre-determined
time-point. The variables evaluated included: proportion
of patients receiving OCS as maintenance therapy; total
daily OCS dose; change from baseline in OCS dose;
number of patients in whom OCS therapy was stopped,
reduced (without stopping), or increased as compared
with baseline; time to reduction in OCS dose or stop-
ping OCS therapy. Data on ICS use were also collected
at each time-point, including: total daily ICS dose;
change from baseline in ICS dose; number of patients in
whom ICS therapy was stopped, reduced (without stop-
ping), or increased as compared with baseline.
Response to omalizumab was assessed using the physi-
cian’s Global Evaluation of Treatment Effectiveness (GETE)
at approximately Week 16 after the initiation of treat-
ment. OCS use among omalizumab responders (i.e. those
with an “excellent” or “good” response by GETE) andnon-responders (i.e. “moderate” or “poor” response, or
“worsening” asthma) was evaluated. OCS doses were con-
verted to prednisolone equivalents (1 mg prednisone =
1 mg prednisolone; 1 mg methylprednisolone = 1.25 mg
prednisolone).
Safety was assessed by recording the nature and fre-
quency of serious adverse events (SAEs) that occurred
during the registry, which were followed until resolution.
Statistical analysis
All efficacy analyses reported are based on the intent-to-
treat (ITT) population, consisting of all randomized patients
who had at least one post-baseline efficacy assessment. All
safety analyses are based on the safety population, which
included all patients who received at least one dose of
omalizumab and had at least one post-baseline safety
assessment.
Statistical analyses were mainly descriptive. Summary
statistics describing change from baseline in OCS dose,
reduction or cessation of OCS treatment, and time to re-
duction were calculated for all patients receiving main-
tenance OCS therapy at baseline, and for GETE-defined
responders and non-responders.
Results
Patient disposition and baseline characteristics
A total of 943 patients were included in the eXpeRience
registry. Of these patients, 694 (73.6%) completed the
registry and 157 (16.6%) discontinued; status was un-
known for 92 (9.8%). The most common reasons for dis-
continuation were loss to follow-up (n = 52; 5.5%) and
withdrawal of consent (n = 27; 2.9%) [14]. Demographic
and clinical characteristics of the patients receiving OCS
at baseline were comparable with the overall population
(Table 1; [14]). The ITT population included 916 pa-
tients and the safety population included 925 patients.
Of the 263 patients receiving OCS at baseline, the ITT
population included 246 patients and the safety popula-
tion included 263 patients.
OCS use
The most commonly used OCS was prednisone (n = 131
at baseline; 49.8% of all patients receiving OCS). The pro-
portion of patients receiving OCS was lower at Months 12
(16.1%) and 24 (14.2%) than at baseline (28.6%) (Figure 1).
The mean total daily OCS dose (prednisolone equivalent)
decreased between baseline (15.5 mg) and Month 12
(7.7 mg), and continued to decrease between Months 12
and 24 (5.8 mg) (Figure 2).
Among patients receiving OCS at baseline, there was a
reduction in or discontinuation of OCS treatment in 57.1%
and 69.0% of patients at Months 12 and 24, respectively
(Figure 3). The mean (SD) time to reduction or discontinu-
ation of OCS was 198.5 (114.29) days and 291.2 (210.86)
Table 1 Baseline demographics and clinical characteristics of patients in the eXpeRience registry (safety population)
Variable Patients on OCS at baseline Overall population
(n = 263) (n = 925)
Mean age, years (SD) 46.0 (13.3) 45.0 (15.0)
Female, n (%) 169 (64.3) 600 (64.9)
Race, n (%)
Caucasian 246 (93.5) 855 (92.4)
Others 17 (6.5) 70 (7.6)
Mean duration of allergic asthma, years (SD) 20.3 (13.6) [n = 261] 19.4 (13.6)
Positive skin-prick test/RAST for perennial aeroallergens, n (%) 232 (88.2) 816 (88.2)†
History of seasonal allergy, n (%) 177 (67.3) 587 (63.5)†
Smoking history, n (%)
Never smoked 202 (76.8) 719 (77.7)‡
Ex-smoker 52 (19.8) 173 (18.7)
Current smoker 9 (3.4) 30 (3.2)
Asthma clinical symptoms, n (%)
Daytime asthma symptoms 245 (93.2) 838 (90.6)
Limitations of activities 239 (90.9) 795 (85.9)
Nocturnal symptoms/awakenings 218 (82.9) 737 (79.7)
Asthma control (investigator assessment), n (%)
Controlled 3 (1.1) 13 (1.4)†
Partly controlled 42 (16.0) 215 (23.2)
Uncontrolled 218 (82.9) 693 (74.9)
†Data missing for one patient; ‡Data missing for three patients.
RAST, radioallergosorbent test; SD, standard deviation.
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tients (2.6%) at Month 12 and four patients (2.4%) at
Month 24 had an increase in OCS dose.
OCS use according to response
Of the 915 patients assessed using the GETE, 64.2% were





































Figure 1 Proportion of patients on maintenance OCS. n =Number
of evaluable patients at each time point. OCS, oral corticosteroids.non-responders (moderate, 23.4%; poor, 6.8%; worsening
of asthma, 0.5%) based on GETE status; 5.1% had no
assessment. Following the GETE assessment, the vast
majority of responders (98.1%) and ‘moderate’ non-







































Figure 2 Mean total daily OCS dose (prednisolone equivalent)
(ITT population). n = number of evaluable patients at each time-point.
OCS, oral corticosteroids; SD, standard deviation; ITT, intent-to-treat. Error
bars represent SD. Post-baseline data include doses of zero for patients











































No change in dose
Figure 3 Change in status of OCS therapy in patients receiving
maintenance OCS at baseline (n = 246; ITT population). n =Number
of evaluable patients at each time-point. OCS, oral corticosteroids; ITT,
intent-to-treat. Post-baseline data include doses of zero for patients no
longer receiving OCS. Data at each time-point are relative to baseline.
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maintenance OCS treatment decreased from 28.1% at
baseline to 13.8% at Month 12 and 12.1% at Month 24.
Mean (SD) total daily dose (prednisolone equivalent) de-
creased from 15.5 (14.63) mg at baseline to 6.5 (10.13)
mg at Month 12, and 5.1 (8.94) mg at Month 24.
Among GETE non-responders, the proportion of pa-
tients on maintenance OCS treatment decreased from
28.5% at baseline to 20.9% at Month 12 and 17.9% at
Month 24. Mean (SD) total daily dose (prednisolone
equivalent) decreased from 14.7 (10.92) mg at baseline
to 11.3 (12.85) mg at Month 12, and 8.1 (8.99) mg at
Month 24.
ICS use
At baseline, 895 of 916 patients (98%) were receiving
ICS maintenance therapy. Among patients who provided
ICS information, 173 of 705 (24.5%) and 182 of 613
(29.7%) had stopped or reduced ICS use at Months 12
and 24, respectively. The majority of patients did not
change their ICS dose (495 [70.2%] at Month 12 and 389
[63.5%] at Month 24), while 37 patients (5.2%) and 42
patients (6.9%) had an increase in dose at Months 12
and 24, respectively. Mean (SD) total daily ICS doses
(beclomethasone equivalent) decreased from 1675 (947)
μg at baseline to 1461 (950) at Month 12 and 1381 (961)
at Month 24. Mean (SD) percentage reductions in ICS
dose from baseline were 9.6% (49.8) at Month 12 and
11.8% (57.1) at Month 24.
ICS use according to response
Among GETE responders, the mean (SD) ICS dose de-
creased from baseline by 266 (759) μg at Month 12 and313 (819) μg at Month 24, with mean (SD) percentage
reductions of 12.9 (41.8) and 14.8 (47.4), respectively.
Among the responders, 133 of 487 (27.3%) and 137 of
435 (31.5%) had stopped or reduced ICS use at Months
12 and 24, respectively.
Among GETE non-responders, the mean (SD) ICS
dose decreased from baseline by 134 (847) μg at Month
12 and 246 (1122) μg at Month 24, with mean (SD) per-
centage reductions of 2.8 (65.9) and 4.8 (77.9), respect-
ively. Among the non-responders, 40 of 200 (20.0%) and
44 of 164 (26.8%) had stopped or reduced ICS use at
Months 12 and 24, respectively.
Safety
Detailed safety findings from the registry have been pub-
lished previously [14]. Briefly, a total of 64 patients
(6.9%) reported 150 SAEs. Of these, 25 SAEs (16.7%)
were suspected to be related to omalizumab. The most
common SAE was asthma (n = 32, 3.5%), followed by
dyspnoea and pneumonia (both n = 7, 0.8%). Nine deaths
occurred during the registry; none were suspected to be
related to omalizumab (causes of death have been de-
scribed previously [14]).
Discussion
In this registry, omalizumab was associated with a reduc-
tion in maintenance OCS use in patients with uncon-
trolled persistent allergic asthma over a 2-year treatment
period in a real-world setting. Approximately half of the
patients on maintenance OCS at baseline were able to
stop or reduce their OCS dose. In addition, there were
also reductions in maintenance ICS use over the 2 years of
the study. We believe that the observed reductions in
OCS and ICS use reflect improved asthma control during
treatment with omalizumab, and are likely to be associ-
ated with a reduction in the risk of steroid-related adverse
effects. Reductions in OCS use and mean total daily OCS
dose were greater in patients classified as responders to
omalizumab treatment than in non-responders. Neverthe-
less, a reduction in OCS use and mean total daily OCS
dose was seen in non-responders, possibly due to the fact
that the definition of non-responders included patients
with a moderate response to omalizumab (as well as those
with a poor or worsening response). This is highlighted by
the vast majority of moderate ‘non-responders’ continuing
with treatment, following the GETE assessment.
Corticosteroids are widely prescribed to treat inflam-
matory conditions, including asthma, for which they
are often the mainstay of treatment [5]. Patients with
uncontrolled severe asthma may require long-term
maintenance therapy with OCS. However, such use is
associated with serious long-term adverse effects such as
hypothalamic-pituitary-adrenal axis suppression, impaired
glucose tolerance and diabetes, osteoporosis, hypertension,
Braunstahl et al. Allergy, Asthma & Clinical Immunology 2013, 9:47 Page 5 of 7
http://www.aacijournal.com/content/9/1/47and cataract formation. There is therefore a need for
therapies that improve outcomes, have acceptable safety
and tolerability profiles, while allowing reductions in OCS
use [12].
Despite the observed reductions in OCS use, patients
enrolled in the eXpeRience registry had fewer clinically
significant asthma exacerbations after 12 or 24 months’
treatment with omalizumab (annualized mean 1.0 and
0.6, respectively) compared with pre-treatment values
(annualized mean 4.9) [14]. Relatedly, omalizumab was
also associated with reductions in healthcare utilization
(hospitalizations, emergency room visits and unsched-
uled doctor visits), from 6.2 during the 12-month pre-
treatment period to 1.0 per year at Month 12 and 0.5
per year at Month 24 [14]. Annualized numbers of days
of absence from work and school due to asthma were
also lower at Month 12 (3.5 and 1.6 days, respectively)
and Month 24 (1.0 and 1.9 days, respectively) than dur-
ing the 12-month pre-treatment period (26.4 and
20.7 days, respectively) [14].
Our findings are in agreement with those of other
real-life studies of omalizumab. A pooled analysis of data
from French and German patients (n = 346) with severe
persistent allergic asthma showed that omalizumab
treatment for at least 16 weeks was associated with a re-
duction or discontinuation of OCS in 50% of patients re-
ceiving OCS at baseline (n = 84/166) [16]. The mean
reduction in daily OCS dose from baseline was 74.3%
[16]. An additional French historic-prospective study
showed that 48.1% of patients reduced or discontinued
maintenance OCS over a period of ≥5 months of omali-
zumab treatment [17].
Decreased use of OCS subsequent to treatment with
omalizumab has also been shown in observational stud-
ies conducted in Italy [18], Belgium [19], Israel [20]
and the United Kingdom [21]. These studies enrolled
between 22 and 142 patients, who were followed up
for between 16 and 52 weeks. Between 20% and 70% of
patients taking OCS at baseline were able to stop or
reduce treatment, and showed meaningful reductions in
exacerbations rates.
The results of this analysis indicate that a significant
proportion of patients on omalizumab therapy were
classed as responders by physician’s GETE at Week 16.
These results are consistent with omalizumab clinical
trials. In an early randomized controlled study, 53% of
omalizumab-treated patients had an excellent/good re-
sponse to omalizumab, compared with 33% for placebo
[22]; in a more recent study, 72.8% in the omalizumab
plus optimized asthma therapy (OAT) group responded,
compared to 31.2% for OAT alone [23]. However, not all
responses to omalizumab are achieved within the first
16 weeks of therapy, with some patients taking longer to
respond [23].Bousquet et al. demonstrated that the physician’s
GETE at Week 16 is an effective predictor of longer-
term outcomes, including exacerbation rates, overall
asthma control and unscheduled medical interventions
[24]. Subsequently, Bousquet et al. also showed that the
majority of patients classified as responders or non-
responders at Week 16 have the same classification at
Week 32 [23]. Consistent with the findings of Bousquet
et al. [23,24], the present study also indicated that
asthma control (as reflected in OCS use) is improved
to a greater extent among responders to omalizumab,
compared with non-responders, and that these improve-
ments (and the differences between responders and non-
responders) persist between Week 16 and 2 years.
Most of the observational studies conducted with
omalizumab support a reduction in maintenance OCS
dose to improve asthma management. However, in rare
cases, patients receiving omalizumab may present with
systemic hypereosinophilic syndrome or allergic eosino-
philic granulomatous vasculitis (Churg-Strauss syndrome)
[25], and these events are usually, but not always, associ-
ated with a reduction in OCS dose. We did not observe
any cases of either hypereosinophilic syndrome or Churg-
Strauss syndrome in the eXpeRience registry, but we
believe that clinicians attempting OCS reduction or with-
drawal in patients with allergic asthma should be aware
of this.
Despite our positive findings, it is important to recognize
the limitations of observational studies, namely the lack
of a control group and the open-label design.
Conclusions
In conclusion, this 2-year, international and observa-
tional registry, conducted in a real-life setting, confirms
that omalizumab is associated with OCS-sparing effects
in patients with uncontrolled persistent allergic (IgE-
mediated) asthma.
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